{"id":50041,"date":"2022-10-25T16:01:43","date_gmt":"2022-10-25T14:01:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/"},"modified":"2022-10-25T16:01:43","modified_gmt":"2022-10-25T14:01:43","slug":"verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/","title":{"rendered":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0"},"content":{"rendered":"
\n

\nThe partnership\u2019s first-of-its-kind participant-centered model will be critical in advancing clinical IBD research <\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–Verily, an Alphabet company focused on precision health, and the Crohn\u2019s & Colitis Foundation, a non-profit organization dedicated to finding cures for Crohn\u2019s disease and ulcerative colitis and to improving the quality of life of children and adults affected by these diseases, announced today an expanded strategic partnership. The collaboration will focus on building a longitudinal registry to accelerate research in Crohn\u2019s disease and in ulcerative colitis, collectively known as inflammatory bowel disease (IBD).\n<\/p>\n

<\/a><\/p>\n

\nThe registry will establish an infrastructure designed to rapidly answer clinical research questions in IBD, to accelerate treatment development and ultimately improve quality of life for people living with these diseases. It will build on the Foundation\u2019s existing patient communities, including patient research communities, and builds on a pilot effort from the partners, which launched in 2021.\n<\/p>\n

\n\u201cWith this partnership, we aim to establish a model for a new kind of disease registry, one that is participant-focused, tech-enabled, and generates high-quality longitudinal data to power clinical research,\u201d said Amy Abernethy, MD, PhD, President of Clinical Studies Platforms at Verily. \u201cThrough this work, we will generate the data and evidence needed to better understand the causes of the disease and to answer critical illness and treatment questions more efficiently than ever before.\u201d\n<\/p>\n

\nThe registry will capture data directly from patients at time periods in their disease journeys to add depth and context to information collected in a clinical setting. Building a holistic longitudinal record of individuals\u2019 health experiences will help unlock answers to high-impact clinical research questions. Importantly, key features such as symptom and quality of life tracking will help researchers better understand treatment effect and value, which is critical for addressing chronic diseases like Crohn\u2019s disease and ulcerative colitis. Industry and academic researchers will be able to partner on the design of prospective studies and access registry data for observational studies, which will be made available through Verily\u2019s clinical research suite and the Foundation\u2019s existing data platform, IBD Plexus.\n<\/p>\n

\n\u201cTo spur future innovative IBD research, it will be critical to centralize high-quality patient data that is both comprehensive and easily accessible for researchers. Our collaborative disease registry with Verily will become a best-in-class experience for people living with IBD, who will contribute their information, and for researchers, who will explore the data to advance our understanding of treatments and how they can improve the quality of life for patients,\u201d said Caren Heller, MD, MBA, Chief Scientific Officer at the Crohn\u2019s & Colitis Foundation. \u201cThe new model provides a uniquely holistic view of the IBD experience, creating larger and more complete longitudinal data sets and accelerating recruitment of participants for clinical research studies.\u201d\n<\/p>\n

\nThe Foundation and Verily bring deep experience with direct-to-patient registry creation. IBD Partners, sponsored by the Crohn’s & Colitis Foundation, is a web-based partnership of over 15,000 patients with IBD. Verily\u2019s Project Baseline Community Study currently includes over 600,000 participants across a number of therapeutic areas.\n<\/p>\n

\nMillions of people in the United States have been diagnosed with IBD, affecting nearly 1 in 100 Americans. CDC data has shown that adults with IBD are more likely to have other chronic conditions than those without the condition. IBD can cause painful and debilitating symptoms and life-threatening complications, presenting a significant burden for patients, and this partnership aims to accelerate research to advance treatment and potential cures of the disease.\n<\/p>\n

\nAbout Verily<\/b>\n<\/p>\n

\nVerily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from Google X in 2015, Verily\u2019s purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science and healthcare to enable the entire healthcare ecosystem to drive better health outcomes. For more information, please visit verily.com.\n<\/p>\n

\nAbout the Crohn\u2019s & Colitis Foundation<\/b>\n<\/p>\n

\nThe Crohn’s & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn’s disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation\u2019s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia
\n
Steven Cooper
\n
Head of Media Relations, Verily
\n
press@verily.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The partnership\u2019s first-of-its-kind participant-centered model will be critical in advancing clinical IBD research SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–Verily, an Alphabet company focused on precision health, and the Crohn\u2019s & Colitis Foundation, a non-profit organization dedicated to finding cures for Crohn\u2019s disease and ulcerative colitis and to improving the quality of life of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50041","6":"format-standard","7":"category-industry"},"yoast_head":"\nVerily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"The partnership\u2019s first-of-its-kind participant-centered model will be critical in advancing clinical IBD research SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–Verily, an Alphabet company focused on precision health, and the Crohn\u2019s & Colitis Foundation, a non-profit organization dedicated to finding cures for Crohn\u2019s disease and ulcerative colitis and to improving the quality of life of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T14:01:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0\",\"datePublished\":\"2022-10-25T14:01:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/\"},\"wordCount\":836,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005203\\\/en\\\/1611947\\\/21\\\/Ver_Wordmark_RGB_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/\",\"name\":\"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005203\\\/en\\\/1611947\\\/21\\\/Ver_Wordmark_RGB_copy.jpg\",\"datePublished\":\"2022-10-25T14:01:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005203\\\/en\\\/1611947\\\/21\\\/Ver_Wordmark_RGB_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221025005203\\\/en\\\/1611947\\\/21\\\/Ver_Wordmark_RGB_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/","og_locale":"en_US","og_type":"article","og_title":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend","og_description":"The partnership\u2019s first-of-its-kind participant-centered model will be critical in advancing clinical IBD research SOUTH SAN FRANCISCO, Calif. & NEW YORK–(BUSINESS WIRE)–Verily, an Alphabet company focused on precision health, and the Crohn\u2019s & Colitis Foundation, a non-profit organization dedicated to finding cures for Crohn\u2019s disease and ulcerative colitis and to improving the quality of life of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-25T14:01:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0","datePublished":"2022-10-25T14:01:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/"},"wordCount":836,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/","url":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/","name":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg","datePublished":"2022-10-25T14:01:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221025005203\/en\/1611947\/21\/Ver_Wordmark_RGB_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/verily-and-crohns-colitis-foundation-expand-strategic-partnership-to-establish-novel-registry-of-patients-with-inflammatory-bowel-disease-ibd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Verily and Crohn\u2019s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD)\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50041"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50041\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}